Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Benefit-risk assessment of bevacizumab in the treatment of breast cancer.

Benefit-risk assessment of bevacizumab in the treatment of breast cancer. Drug Saf. 2012 Jan 01; 35(1):15-25.

View in: PubMed

© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.